Slides
Page 1
JP Morgan Healthcare Conference January 12, 2026 Patrick Kaltenbach, CEO
Page 2
Safe Harbor Statement 2 Statements in this presentation which are not historical facts constitute “forward looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause our or our businesses, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. For a discussion of these risks and uncertainties, please see "Factors Affecting Our Future Operating Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the most recently completed fiscal year and other reports filed with the SEC from time to time.
Page 3
0 100 200 300 400 500 600 700 800 14 15 16 17 18 19 20 21 22 23 24 25 Long Term Track Record of Performance 3 (1) Represents non-GAAP financial measures; a reconciliation to US GAAP metrics is provided in the appendix. $5.00 $15.00 $25.00 $35.00 $45.00 14 15 16 17 18 19 20 21 22 23 24 2,000 2,600 3,200 3,800 14 15 16 17 18 19 20 21 22 23 24 in mUSD Growing Sales (1) LC CAGR: 6% Expanding Operating Margins (1) CAGR: 13% Strong EPS Growth (1) 19% 22% 25% 28% 31% 14 15 16 17 18 19 20 21 22 23 24 Excellent Shareholder Returns S&P 500 CAGR: 16% +1,100 bps
Page 4
End Markets and Applications We Serve Balanced sales mix across attractive market segments Life Sciences, Food Manufacturing, and Chemical markets represent over 70% of sales and benefit from favorable long-term structural growth drivers Attractive end markets that reward automation and productivity, and digitalization/compliance Approximately 2/3 of sales to Life Science customers are to quality labs and manufacturing, while 1/3 supports research and development activities Diversified customer base - no end customer is > 1% of sales 4 Life Sciences ~40% Food Manufacturers ~20% Chemical ~13% Other* ~28% Management estimates for 2025 based on Nov-25 guidance. *Other end market includes Food Retail, Academia, Metal/Plastic/Electronics, Transport & Logistics, etc Sales by End Market Sales by Application Laboratory ~56%Core Industrial ~24% Product Inspection ~15% Food Retail ~5% Sales by Product Production ~50% QA / QC Labs ~20% Research & Development ~20% Other ~10%